May 13, 2022
Article
In this companion article, David S. Hong, MD, considers the safety and efficacy of the first-generation TRK inhibitor larotrectinib and discusses how acquired resistance may affect research into second-generation agents.
April 27, 2022
Article
In the third video interview of the series, David S. Hong, MD, from the University of Texas MD Anderson Cancer Center discusses the safety and efficacy of first-generation TRK inhibitors and reflects on challenges affecting next-generation TRK inhibitors including research into mechanisms of treatment resistance.
March 25, 2021
Video
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, shares his enthusiasm for ongoing research efforts to optimize treatment for patients with advanced solid tumors who harbor NTRK gene fusions.
March 25, 2021
Video
Important takeaways from recent safety and efficacy data presented on the use of larotrectinib as treatment for advanced differentiated and anaplastic thyroid cancers with NTRK gene fusions.
March 25, 2021
Video
Dr David S. Hong reacts to updated survival data associated with the use of larotrectinib as treatment for TRK fusion–positive non–small cell lung cancer.
March 25, 2021
Video
The significance of recent data exploring larotrectinib, a TRK inhibitor, in a subset of patients with TRK fusion–positive tumors with CNS (central nervous system) metastasis.